Latest New Zealand News

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Renowned boosts its US footprint with a landmark RE/MAX partnership and expands multi-year brokerage deals in Australia and New Zealand, driving 3% group revenue growth and positive cash flow in Q3 FY26.

hipages Group (ASX:HPG) has kicked off an on-market buy-back of up to 10% of its shares, signalling confidence in its undervalued stock amid strong cash flow and growth.

hipages Group has acquired a majority stake in VIZ Insurance, marking its strategic entry into the insurance sector for tradies and broadening its platform offerings.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Woolworths Group posted a 4.5% increase in third quarter sales, led by strong Australian Food and WooliesX eCommerce growth, while signaling cautious EBIT guidance due to inflation and Middle East conflict impacts.

T&G Global is moving to sell its New Zealand fresh produce and Pacific Island businesses as part of a strategic pivot to concentrate on its premium Apples and VentureFruit platforms. The divestments, pending contract finalisation, mark a significant reshaping of the company’s portfolio amid shareholder shifts.

Syntara Limited has raised A$10 million through a two-tranche placement and share purchase plan, backing its Phase 2b myelofibrosis trial and multiple clinical readouts following positive FDA feedback.

Pacific Equity Partners has tabled a non-binding offer to acquire oOh!media for A$1.40 per share via a scheme of arrangement, triggering a strategic review by the board amid regulatory hurdles and due diligence conditions.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Axtec Limited has sold its PaySure loan book to Real Flow and secured a minority stake in the fintech, marking a strategic shift towards a platform-focused, AI-driven distribution model.